Anglo-Swedish drug major AstraZeneca (LSE: ANZ) has announced positive results from a Phase III trial of its combination antibiotic Zavicefta (ceftazidime-avibactam).
The REPROVE trial assessed the efficacy of Zavicefta compared to meropenem in the treatment of adult patients with hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).
The new antibiotic met the primary objective of statistical non-inferiority compared to meropenem at the test of cure visit (day 21 from randomization). All-cause mortality rate at day 28 from randomisation was also similar in the two groups.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze